The content on this site is intended for healthcare professionals only
Dr Harvey Pass speaks about a novel biomarker test that is believed to be the most accurate yet in detecting proteins secreted from tumours caused by exposure to asbestos. In a blinded test the proteomic assay could detect 15 of 19 cases of malignant pleural mesothelioma that were in stage 1 or stage 2, making the test about 80 percent sensitive, a measure of how accurately a test can identify disease. In addition, the specificity of the test was 100 percent, meaning there were no false positives in this study. To view the slides click here.
Tepotinib in second line NSCLC treatment
Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC
New classification for identifying HR myeloma based on cytogenetic abnormalities
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
TROP2 expression measured by QCS is a promising predictor of clinical outcomes in patients with mNSCLC
Choosing Wisely in endometrial & cervix cancers: Medical therapy
Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy
ESMO 2024: Latest in EGFR mutated NSCLC
